Farooq Omer, Habib Asad, Shah Masood Alam, Ahmed Najia
Dr. Omer Farooq, MBBS, FCPS, FRCS. Department of Ophthalmology, PNS Shifa Hospital, BUMDC, Karachi, Pakistan.
Dr. Asad Habib, MBBS. Department of Ophthalmology, PNS Shifa Hospital, BUMDC, Karachi, Pakistan.
Pak J Med Sci. 2019 Nov-Dec;35(6):1544-1547. doi: 10.12669/pjms.35.6.896.
To determine the efficacy of oral eplerenone in anatomical and functional improvement in patients with chronic central serous chorioretinopathy (CSCR).
This quasi experimental study was performed at PNS Shifa Hospital Karachi from September 2018 to February 2019. Study included 23 patients. Patients were included using consecutive sampling technique and informed consent was taken from all patients before staring treatment. 50 mg of oral eplerenone per day was given for three months. Subretinal fluid (SRF) height and visual acuity (VA) were noted at baseline, one month and three month follow-up. Structured Study performa was used for data collection. Data was analysed and assessed with SPSS version 23. P value of <0.05 was considered statistically significant.
Mean age of patients was 40.7±7 years and mean duration of disease before treatment was 3.7±0.76 months. Mean baseline BCVA and SRF height was 0.39±0.02 logMAR and 123±12.5 µm respectively. Sixty-five percent patients responded at one month and 80% at three months with reduction in SRF height. Improvement in visual acuity was also statistically significant at 3 months (p<0.05).
Use of eplerenone in chronic CSCR resulted in significant improvement in vision and decrease in mean SRF height.
确定口服依普利酮对慢性中心性浆液性脉络膜视网膜病变（CSCR）患者解剖结构和功能改善的疗效。
本准实验研究于2018年9月至2019年2月在卡拉奇的PNS Shifa医院进行。研究纳入23例患者。采用连续抽样技术纳入患者，在开始治疗前从所有患者处获得知情同意。每天给予50毫克口服依普利酮，持续三个月。在基线、1个月和3个月随访时记录视网膜下液（SRF）高度和视力（VA）。使用结构化研究表格进行数据收集。数据采用SPSS 23版进行分析和评估。P值<0.05被认为具有统计学意义。
患者的平均年龄为40.7±7岁，治疗前疾病的平均持续时间为3.7±0.76个月。平均基线最佳矫正视力（BCVA）和SRF高度分别为0.39±0.02 logMAR和123±12.5 µm。65%的患者在1个月时出现反应，80%的患者在3个月时出现反应，SRF高度降低。3个月时视力改善也具有统计学意义（p<0.05）。
在慢性CSCR中使用依普利酮可显著改善视力并降低平均SRF高度。
